PAVMHealthcare · Medical DevicesThe 2 Wall Street analysts covering PAVmed, Inc. hold a median 12-month price target of $37 — +1752.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores PAVmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PAVM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1752.8% from it.
Of the 18 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2026 | Ascendiant Capital | Maintains | Buy | $56 → $57 |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | $65 → $56 |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 10 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 9 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 10 Sept 2024 | Ascendiant Capital | Maintains | Buy | $22 → $21 |
| 18 Aug 2023 | Cantor Fitzgerald | Reiterates | Neutral | $1.40 |
| 20 Jan 2023 | Cantor Fitzgerald | Downgrade | Neutral | $4.00 → $1.50 |
| 18 Jan 2023 | Lake Street | Maintains | Buy | $5.00 → $1.50 |
| 17 Aug 2022 | Lake Street | Maintains | Buy | $7.00 → $5.00 |
| 30 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 5 Nov 2020 | Ascendiant Capital | Initiates | Buy | — |
| 13 Oct 2020 | Lake Street | Initiates | Buy | — |
| 28 June 2018 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PAVM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, PAVmed, Inc. returned −85.0% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 3% of US stocks
Cheaper than 84% of US stocks
Cheaper than 67% of US stocks
Higher than 98% of US stocks
Higher than 95% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 18% of US stocks
Higher than 10% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PAVmed, Inc. has a market value of $17.1M and an enterprise value of $16.1M.
Revenue in the twelve months to 30 June 2026: $112K. The latest quarter grew 450.0% year on year.
Net income over the same four quarters: −$16.4M, a −14669.6% net margin.
Diluted earnings per share, trailing twelve months: $−75.49.
Free cash flow in the twelve months to 30 June 2026: −$7.8M.
Trailing P/E: 0.1×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
PAVmed, Inc. employs 41 people — $3K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PAVmed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lucid Diagnostics, a subsidiary of PAVmed, announced it will hold a business update conference call and webcast on November 12, 2026, at 8:30 a.m. ET.
Why it matters — Lucid is a PAVmed subsidiary, so its business update is relevant to PAVM watchers.
Lucid Diagnostics, a PAVmed subsidiary, began receiving Medicare payments for its EsoGuard test at its established Clinical Laboratory Fee Schedule rate. It also closed a $15 million Series C preferred-stock private placement with existing long-term shareholders.
Why it matters — The Medicare payments and financing are developments at PAVmed’s subsidiary that the company says support its balance sheet, cash runway, and near-term commercial acceleration.
Lucid Diagnostics, a subsidiary of PAVmed, announced advances in payment, billing, and coding pathways for its EsoGuard and EsoCheck products. A Medicare advisory panel recommended keeping EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule, the AMA approved a new Category III CPT code for non-endoscopic cell collection with EsoCheck, and a proposed ICD-10-CM diagnosis code for positive EsoGuard results received a favorable response from the CDC/NCHS committee.
Why it matters — These coding, billing, and payment milestones could help broaden reimbursement and adoption for PAVmed's subsidiary products.
PAVmed Inc. held its second-quarter 2026 earnings call, and Seeking Alpha published the full transcript of the discussion. The transcript covers the company's Q2 2026 results and management commentary from the call.
Why it matters — PAVmed watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's own commentary on its operations.
PAVmed provided a business update and reported financial results for the second quarter ended June 30, 2026. The update noted that Veris Health accelerated commercial engagement with OSU-The James, its implantable physiological monitor achieved development milestones toward an upcoming FDA submission, and Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard. A conference call and webcast were held August 14, 2026.
Why it matters — PAVmed watchers would care because these milestones mark tangible progress for its subsidiaries, including Veris Health advancing its monitor toward an FDA submission and Lucid Diagnostics gaining its first coverage policy for EsoGuard.
The 2 Wall Street analysts covering PAVmed, Inc. have a median 12-month price target of $37, with estimates ranging from $16 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering PAVmed, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PAVmed, Inc. 22 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, PAVmed, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1752.8% from the last close, and Ticker Nerd's factor model ranks PAVmed, Inc. 22 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PAVmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $57 over the next 12 months.
PAVmed, Inc. returned -85.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pavmed Inc. is a diversified commercial-stage medical technology company focused on developing, acquiring, and commercializing products across medical devices, diagnostics, and digital health.
The most recent item we track (PRNewsWire, 29 Oct 2026): "Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026". Lucid Diagnostics, a subsidiary of PAVmed, announced it will hold a business update conference call and webcast on November 12, 2026, at 8:30 a.m. ET.
Pavmed Inc. is a diversified commercial-stage medical technology company focused on developing, acquiring, and commercializing products across medical devices, diagnostics, and digital health. The company’s portfolio addresses unmet clinical needs in areas such as gastrointestinal endoscopy, cancer detection, remote patient monitoring, vascular access, and other minimally invasive care settings. Through its operating subsidiaries, Pavmed supports products and platforms designed for use by healthcare providers, hospitals, and patients, with an emphasis on improving workflow, diagnosis, and care delivery. Its current business is centered on bringing novel healthcare technologies into commercial use and expanding access to tools that support prevention, treatment, and ongoing patient management.
CEO Dr. Lishan Aklog M.D. · 41 employees · United States · https://www.pavmed.com
